ADDISON, Texas, Aug. 26, 2013 /PRNewswire/ -- ULURU Inc.
(OTCQB: ULUR), today announced the publication in the
International Wound Journal of an article titled, "A prospective,
randomized study of a novel transforming methacrylate dressing
compared with a silver-containing sodium carboxymethylcellulose
dressing on partial-thickness skin graft donor sites in burn
patients."
This controlled randomized study was conducted at the
University of Texas Southwestern Medical
Center evaluating Altrazeal® compared with
Aquacel Ag, the market leading silver containing dressing. Patients
were treated with both products on 2 separate donor sites.
Donor sites treated with Altrazeal® experienced
statistically significant less pain at three different time periods
(2-5 days, 6-10 days and 11-15 days – P < 0.001). Patients also
reported greater comfort with Altrazeal® (P < 0.001).
These findings are considered to be clinically beneficial as pain
and patient comfort are major issues in donor site management.
Commenting on the publication, Kerry P.
Gray, President and CEO of ULURU, stated, "Having a
published controlled randomized study using Altrazeal®
against a market leading product is very significant and adds great
credibility to Altrazeal®. Many marketed wound care
products are not supported by clinical data of this quality. The
study's finding of a significant reduction in pain is very
important as numerous painful wounds, including venous leg ulcers,
are difficult to treat due to patient compliance issues associated
with pain and discomfort. This controlled study also confirms the
vast amount of anecdotal evidence we have had reported on pain
reduction. To further enhance the data supporting
Altrazeal®, we intend conducting additional controlled
studies to demonstrate clinical benefits for patients and cost
savings for the healthcare payor."
About ULURU Inc.:
ULURU Inc. is a specialty
pharmaceutical company focused on the development of a portfolio of
wound management and oral care products to provide patients and
consumers improved clinical outcomes through controlled delivery
utilizing its innovative Nanoflex® Aggregate technology
and OraDisc™ transmucosal delivery system. For further
information about ULURU Inc., please visit our website at
www.ULURUinc.com. For further information about
Altrazeal®, please visit www.Altrazeal.com.
This press release contains certain statements that are
forward-looking within the meaning of Section 27a of the Securities
Act of 1933, as amended. These statements are subject to
numerous risks and uncertainties, including but not limited to the
importance of pain reduction in wound care and the demonstration of
cost savings and clinical benefits, and the risk factors detailed
in the Company's Annual Report on Form 10-K for the year ended
December 31, 2012, and other reports
filed by us with the Securities and Exchange Commission.
Contact: Company
Kerry P. Gray
President & CEO
Terry K. Wallberg
Vice President & CFO
(214) 905-5145
SOURCE ULURU Inc.